Morgan Stanley to Juno

The potential of Juno Therapeutics Inc. to shift the cancer treatment paradigm coupled with the cancer immunotherapy play's clinical data and management team were enough to lure Steve Harr away from Morgan Stanley after 12 years at the bank.

Last month, Juno said Harr will join as CFO and head of corporate development...